TheGridNet
The Vienna Grid Vienna

Vienna
Breaking News

Live English Tutors
Restaurants Nachrichten Wetterradar Verzeichnis

Top-Geschichten

Vienna Politics Nachrichten

Vienna is establishing a service point in the city hall
Vienna is establishing a service point in the city hall
Vor 2 Jahren
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
Vor 2 Jahren
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Vor 2 Jahren
Austria sees sharp rise in acts of antisemitism
Austria sees sharp rise in acts of antisemitism
Vor 2 Jahren
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Vor 2 Jahren
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
Vor 2 Jahren
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Vor 2 Jahren
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Vor 2 Jahren
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Vor 2 Jahren
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Vor 2 Jahren